A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy
Not Applicable
Completed
- Conditions
- Mycobacterium Avium-Intracellulare InfectionHIV InfectionsTuberculosis, Mycobacterium Infection
- Registration Number
- NCT00002085
- Lead Sponsor
- Pfizer
- Brief Summary
To evaluate the efficacy and safety of azithromycin given chronically for the treatment of serious nontuberculous mycobacterial infection in patients failing or intolerant of other available therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie azithromycin's efficacy in nontuberculous mycobacterial infections?
How does azithromycin compare to standard-of-care regimens for Mycobacterium avium-intracellulare in HIV-positive patients?
Which biomarkers correlate with treatment response to chronic azithromycin in NTM disease?
What are the long-term adverse event profiles of azithromycin for NTM infections in immunocompromised populations?
Are there synergistic combination therapies involving azithromycin and other macrolides for drug-resistant mycobacterial infections?
Trial Locations
- Locations (2)
Pfizer Central Research
🇺🇸Groton, Connecticut, United States
Natl Cancer Institute / Metabolism Branch
🇺🇸Bethesda, Maryland, United States
Pfizer Central Research🇺🇸Groton, Connecticut, United States